MEDICALLY REVIEWED

Semaglutide (Rybelsus®) receives FDA approval as first line treatment for Type 2 Diabetes Mellitus

Novo Nordisk
Semaglutide, available in oral and subcutaneous dosage forms, is a selective glucagon-like peptide-1 receptor agonist with 3 main mechanisms of action.

Log In or Register as a healthcare professional to read the full article.

Share via

Also worth reading

People also read:

MIT Vibrating Capsule
MIT Scientists Develop Vibrating Capsule To Treat Obesity

The vibrating capsule, likened to the feeling of drinking a glass full of water before eating, targets the brain’s perception of satiety. When ingested 20 minutes prior to a meal, it stimulates mechanoreceptors, which in turn signal the brain via the vagus cranial nerve. This signal initiates the production of hormones such as insulin, GLP-1, C-peptide, and PYY, reducing hunger and enhancing the digestion process. In animal models, this mechanism resulted in a reduction of food consumption by about 40%.

Read More »
bangkok government healthcare
Weekly Asian Medical News Bulletin – 20 October 2023

Health experts suggest Malaysia’s budget for the Madani medical scheme, targeting lower-income groups, should be increased and doubled to decongest public healthcare facilities. There are calls for more apparent strategies on new health initiatives and reallocating sugar-sweetened beverages tax revenue for preventive health measures. Concerns also extend to the underfunding of healthcare digitalisation and the need for stronger public-private partnerships in healthcare service delivery.

Read More »